Merck pens pact with Pearl Bio for new biologics in cancer
Merck is teaming up with a Khosla Ventures-backed biotech in a package that could be worth as much as $1 billion to create new biologics …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
